-85°,O, of their former levels. No change was noted in the size of spleen or lymph nodes. Each treatment pr obably destroyed 4-8 x 101l cells, some 1000 of the total tumour load. The antibody was rapidly consumed, and there was evidence of heavy utilization of complement.
CERTAIN NEOPLASMS of B lymphocytes insert immunoglobulin (Ig) molecules into their surface membranes but do not export them in amounts sufficient to give detectable electrophoretic bands in serum. The group thus defined includes most cases of chronic lymphocytic leukaemia (CLL) and non-Hodgkin lymphoma (Grey et al., 1971; Leech et al., 1975; Johansson et al., 1976) . Among the antigenic determinants on this surface Ig are idiotypic determinants, which can be regarded as highly specialized differentiation antigens. On individual B lymphocytes all the Ig molecules bear the same idiotypic determinants, but among the total population of normal B lymphocytes the determinants present a wide spectrum. When one B lymphocyte divides to initiate a clone of cells, normal or neoplastic, the Ig molecules within the clone preserve the parental idiotypic determinants.
Antibody to the idiotypic determinants on B lymphocytic neoplasms reacts with 36 the neoplastic cells and with only a negligible proportion of normal lymphocytes (Stevenson & Stevenson, 1975; Hough et al., 1976; Haughton et al., 1978; Krolick et al., 1979) . Raising the antibody is an individual requirement for each tumour. Our method involves immunizing a foreign species, usually sheep, with Fab liberated from the cell-surface Ig by limited proteolysis with papain. Six weeks elapse between receipt of the tumour cells in the laboratory and provision of the anti-idiotype.
A therapeutic potential for xenogeneic anti-idiotype (anti-Id) has been demonstrated in experimental lymphocytic leukaemias of guinea-pig (Stevenson et al., 1977b) and mouse (Haughton et al., 1978; Krolick et al., 1979) . Administration of antibody to animals bearing these fastgrowing tumours has retarded the disease, and under some circumstances small tumour loads appear to have been ablated entirely. In the present paper we record some early observations on the use of anti-Id in treating a B lymphocytic leukaemia in man. PATIENT C.W., a white male aged 73, was diagnosed in May 1978 as having CLL with features characteristic of the prolymphocytic variant (Galton et al., 1974) . On presentation there was an enlarged left axillary node, splenomegaly 6 cm below the costal margin, and a white-cell count 92 x 109/1 with 99% lymphocytes. Serum IgG was 8-7 g/l, IgA 0 3 g/l and IgM 0-6 g/l, with no monoclonal band apparent. (Porath et al., 1967) : for immunosorbents, 10 mg IgG to 1 ml packed Sepharose 4B-CL (Pharmacia); for radioimmunoassays, 0 4 mg IgG to 1 ml Sephadex G-25 superfine (Pharmacia).
Anti-Id directed against idiotypic determinants on the surface IgM of C.W. leukaemic cells was prepared by a modification of our original method (Stevenson & Stevenson, 1975) . 4 x 1010 well washed C.W. lymphocytes from a leukapheretic sample were suspended in 50 ml of phosphate-buffered saline, pH 7 4, and subjected to limited proteolysis with papain (0-6 mg/ml, 37TC, 60 min) so as to cleave the surface IgM in situ and release Fab,tu into the supernatant (Eady et al., 1974) The animals were bled a week later, and 300 ml of antiserum from the better responder was processed for therapy. Antibody activity against the constant regions of the Fablu (anti-C, and anti-CA totalling about 5 mg/ ml) was removed by passing the serum through an immunosorbent column containing immobilized human IgMA. The serum then contained antibody seen by indirect immunofluorescence to react with the surface Ig of C.W. lymphocytes, but not with lymphocytes from 2 other cases of CLL, nor with normal lymphocytes.
Antibody-containing IgG was prepared from anti-Id serum by sequential precipitation with 1-6M (NH4)2SO4 and chromatography on DEAE-cellulose. To prepare the IgG2 subclass, the DEAE-cellulose was run in 0-02M phosphate, pH 7-2; after delivery of the IgG2, the IgGi subclass was eluted With 0-14M NaCi, 0-02M phosphate, pH 7-2.
These IgG fractions all exhibited the same anti-Id activity as the parent serum. Using the standard battery of Transfusion Centre tests they showed no activity against C.W. red cells nor against a panel of human red cells.
One-gram lots of monodisperse (i.e. aggregate-free) IgG1 for i.v. infusion were prepared by passing IgG, obtained as above through Sephacryl S300 (Pharmacia) equilibrated with sterile physiological saline. Immediately before infusion each preparation passed a pyrogen test in rabbits (European Pharmacopoeia, 1971 ).
Solid-phase radioimmunoassays (Eady et al., 1977) were used to quantify IgM secretion by C.W. cells, and the level of sheep IgG in C.W. plasma. For the former assay the immobilized antibody was sheep purified anti-C.1, and the radiolabelled antigen human normal pentameric IgM. For the latter the immobilized antibody was rabbit purified anti-sheep Fcy (absorbed with human Ig), and the radio-labelled antigen, sheep normal IgGi.
Determinations of lysis of C.W. cells by antibody and complement were carried out as described previously (Stevenson et al., 1977a) . Percentages of specific 51Cr-release were taken as:
Counts released by antibodycounts released by normal IgG x 100
Counts released by detergentcounts released by normal IgG where detergent lysis was carried out in Nonidet P40.
RESULTS
Studies before immunotherapy Access of anti-Id to the patient's cells would be hampered by any idiotypepositive Ig secreted by the cells. When cultured in vitro they were seen to secrete both IgM and IgD into the supernatant, the latter at less than 10 % the rate of the former (Fig. 1) . Chromatography on Ultrogel AcA 34 revealed the IgM to be pentameric. It was also shown to bear the idiotypic determinants present on the cell-surface Ig: an immunosorbent prepared with anti-Id bound all the 1gM, whereas immunosorbent with antibody against the surface idiotype of another patient (0. J., also with CLL) bound no significant amount. The production rate depicted in Fig. 1 IgG prepared from anti-Id serum was able to kill the leukaemic cells in vitro by activating human complement (Fig. 2) . Lysis was inhibited completely by the chelating agent EGTA, indicating that the complement was being activated via its classical pathway (Fine et al., 1972) . The minor subclass IgG2 (known to have little or no complement-activating activity (Grant et al., 1975; Stevenson & Elliott, 1978) ) not only failed to induce killing of the cells, but appeared also to have blocking activity: whole IgG, comprising Subclasses 1 and 2, is seen in Fig. 2 to have been less effective than IgG1 alone in invoking complement lysis.
In the experiment depicted in the On the afternoon of 6 November 1979, the patient underwent a further 41 plasma exchange, replacement on this occasion consisting of 2 1 of plasma protein fraction and 2 1 of fresh frozen plasma. 750 mg of antibody-containing IgG1 in 500 ml of physiological saline was then infused over 6 h. There was no bronchospasm, but a rigor occurred 3 h into the infusion, and his temperature rose to 37-8°C. The infusion was not interrupted and the pyrexia had subsided 2 h after its completion. Twentyfour h later 500 ml of fresh frozen plasma was infused, followed by a further 420 mg of IgG1 in 500 ml of physiological saline given over 6 h. There were no untoward effects on this occasion. On both of the next 2 mornings 500 ml of fresh frozen plasma was infused.
Sequels of antibody administration
The pleting each treatment the first counts revealed falls, and over the subsequent 36-72 h these falls continued to nadirs of 66% and 50% of the pre-treatment counts for the first and second treatments respectively. The counts then increased, so that in each case by 8 days after the treatment they had reached about 85% of their pretreatment levels. Throughout this time no significant changes were detected in neutrophil counts or haemoglobin levels. In Fig. 3 the effects can be compared with those of therapeutic leukaphereses, with the reservation that the breadths of the post-leukapheresis troughs are exaggerated by the fact that blood counts were not conducted daily, as they were when assessing antibody treatments. Leukapheresis was always accompanied by a worrying reduction (up to 30%) in platelet count, but there was no reduction after either antibody treatment.
No change was noted clinically in the size of spleen or lymph nodes in the week after either antibody treatment. Nor was there any significant difference in 4 radioisotopic scans of the spleen: before each treatment, 6 days after the first, and 7 days after the second.
After each treatment there was evidence of consumption of complement: C3 and C4 levels, already diminished by plasma exchange, fell further, and were slow to recover. The complement conversion product 03c was detected in the patient's plasma 18 h after the first treatment, and in smaller amount 9 h after the second infusion of the second treatment (Strong & Watkins, 1979 (Gorer, 1942) and more recent evidence (Proctor et al., 1973) suggests that they can ablate micrometastases. The presence on B-lymphocytic neoplasms of Ig idiotypes, about which a great deal is known at the molecular level (Capra & Kehoe, 1975) offers in anti-Id an opportunity for studying the preparation and action of tumour-specific antibody with some precision. The system has the disadvantage of requiring the raising of a different antibody for each tumour, but the idiotypic determinants appear to be reliably strong immunogens. Some therapeutic activity of anti-Id has been demonstrated in animals (Stevenson et al., 1977b; Haughton et al., 1978; Krolick et al., 1979) although the malignancy of the experimental tumours renders extrapolation to man uncertain. The patient described in the present report had a rapidly advancing leukaemia not subjected to chemotherapy (the prolymphocytic variant characteristically responds poorly to such treatment (Galton et al., 1974) ) and so offered an excellent opportunity for preliminary evaluation of the antibody in man.
At this early stage some of our strategy (choice of the IgGi subclass and supplementation of the patient's complement) is based on the assumption that the major killing agent to be invoked by the antibody will be complement, the activation of which at the cell surface can lead to lysis and opsonization. A limited amount of evidence available from animal work supports this assumption (Kassell et al., 1973; Bernstein et at., 1980) . Other pos-500 sible anti-tumour mechanisms operative through antibody include simple metabolic perturbation (Virji & Stevenson, 1979) complement-independent opsonization (Fakhri et al., 1973 ) and K-cell lysis (MacLennan, 1972) . In sheep antibodies, K-cell lysis is promoted by the IgG2 subclass (Stevenson & Elliott, 1978) which was removed from our preparation because of its blocking activity for complement lysis.
Antibody was given i.v. in order to avoid the pain associated with large i.m. injections of IgG, and because i.v. nonaggregated antigen frequently induces tolerance rather than immunization (Dresser, 1962) . The first reaction observed in our patient, bronchospasm, was not seen during the second and third infusions, which were given at a much slower rate than the first. It possibly arose from the action of anaphylatoxins, C3a and C5a (Hugli & Miiller-Eberhard, 1978 ) released when antibody-antigen reactions activated complement; a reaginic mechanism is unlikely in view of the repeated failure of sheep IgG to give a skin reaction. The pyrexia observed some hours after the start of the first and second infusions was surprising in view of the steps taken to exclude pyrogens from the antibody preparations. Possibly it arose from widespread phagocytosis by neutrophils, which promoted a slow release of endogenous pyrogen (Berlin & Wood, 1964 2-3 days. In view of the very rapid consumption of antibody we assume that there can have been little depletion of extravascular lymphocytes. The estimates of cells removed might be low, due to replenishment of the vascular compartment while the count was falling, or might be high, due to an unexplained migration of cells from the blood.
The rapid resurgence of the blood lymphocyte count after leukapheretic or immunological depletion is consistent with the existence of a large readily accessible pool of tissue CLL cells (Manaster et al., 1973; Theml et al., 1973) . However, some CLL cells in tissues (and apparently in the marrow particularly (Theml et al., 1973; Scott et al., 1973) ) exchange poorly with the blood, so it has proved difficult to assess the sizes of the various cellular compartments of this neoplasm. In our patient, with only modest splenomegaly and lymphadenopathy, it seems likely that the tumour burden in the blood at the time of study (-1.5 x 1012 cells) represented at least 20-30% of the total. On this basis the reduction in blood count after each treatment represented on average a removal of some 10O% of the total tumour.
These preliminary results demonstrate that anti-Id is by itself capable of limited killing of Ig-bearing neoplastic lymphocytes, possibly via the activation of complement. Elaborations of its use which might be envisaged include combination with cytotoxic therapy, linkage to toxin or radioisotope, or clearance of idiotypebearing tumour cells from autologous marrow destined for re-implantation.
